For subcutaneous or intravenous use in dogs and cats.
The veterinary medicinal product should be injected subcutaneously or intravenously, once daily, at a dose of 1 mg/kg bodyweight (1 ml/10 kg bodyweight) for up to 5 consecutive days. Intravenous administration of the veterinary medicinal product should be given as a single bolus without mixing the veterinary medicinal product with any other fluids.
To prevent vomiting, the veterinary medicinal product should be administered more than 1 hour in advance. The effect duration is approximately 24 h and therefore treatment can be given the night before administration of an agent that may cause emesis e.g. chemotherapy.
As the pharmacokinetic variation is large and maropitant accumulates in the body after once daily repeated administration, lower doses than recommended might be sufficient in some individuals and when repeating the dose.
For administration by subcutaneous injection, see also “Special precautions for use in animals:” (section 4.5 of SPC).
The cap may be safely punctured up to 40 times. It is recommended that a draw-off needle be used to reduce the number of times the septum is punctured.
Use during pregnancy, lactation or lay
Use only according to the benefit-risk assessment by the responsible veterinarian
Conclusive reproductive toxicity studies have not been conducted in any animal species.
Special warnings for each target species
Vomiting can be associated with serious, severely debilitating conditions including gastrointestinal obstructions; therefore, appropriate diagnostic evaluations should be employed. Good veterinary practice indicates that antiemetics should be used in conjunction with other veterinary and supportive measures such as dietary control and fluid replacement therapy while addressing the underlying causes of the vomiting.
Dogs: Although maropitant has been demonstrated to be effective in both the treatment and prevention of emesis induced by chemotherapy, it was found more efficacious if used preventively. Therefore, it is recommended to administer the antiemetic prior to administration of the chemotherapeutic agent.
Cats: The efficacy of maropitant in reduction of nausea was demonstrated in studies using a model (xylazine induced nausea).